# Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

> **NCT05110170** · PHASE3 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 188 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** LY01005
- **DRUG:** ZOLADEX® 3.6 mg

## Key facts

- **NCT ID:** NCT05110170
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-15
- **Primary completion:** 2022-04-05
- **Final completion:** 2022-06-24
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2023-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05110170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05110170, "Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05110170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*